Literature DB >> 27872065

In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Barbara A Brown-Elliott1, Julie V Philley2, David E Griffith2, Foram Thakkar2, Richard J Wallace3,2.   

Abstract

We performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 103 respiratory isolates of Mycobacterium avium complex (MAC), including multidrug-resistant isolates. Approximately 90% of isolates had bedaquiline MICs of ≤0.008 μg/ml, and 102/103 isolates had MICs of ≤0.015 μg/ml. Bedaquiline has excellent potential for use in patients with MAC infections, although for reasons of its metabolism by the cytochrome P450 system, it should not be given with rifampin.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium avium complex; bedaquiline; nontuberculous mycobacteria; susceptibility testing

Mesh：

Substances：

Year:  2017        PMID： 27872065      PMCID： PMC5278735          DOI： 10.1128/AAC.01798-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.

Authors:  Emma Huitric; Peter Verhasselt; Koen Andries; Sven E Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

2.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

3.  ATP synthase inhibition of Mycobacterium avium is not bactericidal.

Authors:  Nacer Lounis; Tom Gevers; Joke Van den Berg; Luc Vranckx; Koen Andries
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

4.  A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.

Authors:  Akos Somoskovi; Vera Bruderer; Rico Hömke; Guido V Bloemberg; Erik C Böttger
Journal:  Eur Respir J       Date:  2014-10-30       Impact factor: 16.671

5.  Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.

Authors:  Ruben C Hartkoorn; Swapna Uplekar; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

6.  Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.

Authors:  Lorenzo Guglielmetti; Damien Le Dû; Mathilde Jachym; Benoît Henry; Diane Martin; Eric Caumes; Nicolas Veziris; Nathalie Métivier; Jérôme Robert
Journal:  Clin Infect Dis       Date:  2014-10-15       Impact factor: 9.079

7.  New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.

Authors:  Elena Segala; Wladimir Sougakoff; Aurelie Nevejans-Chauffour; Vincent Jarlier; Stephanie Petrella
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

Review 8.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

9.  Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.

Authors:  Beth Williamson; Kelly E Dooley; Yuan Zhang; David J Back; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

10.  Bedaquiline: First FDA-approved tuberculosis drug in 40 years.

Authors:  Rajiv Mahajan
Journal:  Int J Appl Basic Med Res       Date:  2013-01
View more
  14 in total

1.  In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China.

Authors:  Xia Yu; XiaoPan Gao; Chenghai Li; Jingjing Luo; Shuan Wen; Tingting Zhang; Yifeng Ma; Lingling Dong; Fen Wang; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates.

Authors:  Simone Mok; Margaret M Hannan; Lars Nölke; Patrick Stapleton; Niamh O'Sullivan; Philip Murphy; Anne Marie McLaughlin; Eleanor McNamara; Margaret M Fitzgibbon; Thomas R Rogers
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 4.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

Review 5.  Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Gail L Woods
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

6.  Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease.

Authors:  David C Alexander; Ravikiran Vasireddy; Sruthi Vasireddy; Julie V Philley; Barbara A Brown-Elliott; Benjamin J Perry; David E Griffith; Jeana L Benwill; Andrew D S Cameron; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2016-12-07       Impact factor: 5.948

7.  In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Byung Woo Jhun; Seong Mi Moon; Su-Young Kim; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 8.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

9.  In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China.

Authors:  Yu Pang; Huiwen Zheng; Yaoju Tan; Yuanyuan Song; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 10.  Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis.

Authors:  Priya Singh; Rashmi Kumari; Rup Lal
Journal:  Indian J Microbiol       Date:  2017-10-24       Impact factor: 2.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.